DE69740060D1 - Nasale verabreichung von substanzen zur behandlung der tardiven emesis - Google Patents

Nasale verabreichung von substanzen zur behandlung der tardiven emesis

Info

Publication number
DE69740060D1
DE69740060D1 DE69740060T DE69740060T DE69740060D1 DE 69740060 D1 DE69740060 D1 DE 69740060D1 DE 69740060 T DE69740060 T DE 69740060T DE 69740060 T DE69740060 T DE 69740060T DE 69740060 D1 DE69740060 D1 DE 69740060D1
Authority
DE
Germany
Prior art keywords
emesis
tardives
substances
treatment
nasal administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69740060T
Other languages
English (en)
Inventor
Mary Psilogenis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evoke Pharma Inc
Original Assignee
Evoke Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evoke Pharma Inc filed Critical Evoke Pharma Inc
Application granted granted Critical
Publication of DE69740060D1 publication Critical patent/DE69740060D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69740060T 1996-03-14 1997-03-13 Nasale verabreichung von substanzen zur behandlung der tardiven emesis Expired - Lifetime DE69740060D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/616,121 US5760086A (en) 1996-03-14 1996-03-14 Nasal administration of agents for treatment of delayed onset emesis
PCT/US1997/003974 WO1997033573A1 (en) 1996-03-14 1997-03-13 Nasal administration of agents for treatment of delayed onset emesis

Publications (1)

Publication Number Publication Date
DE69740060D1 true DE69740060D1 (de) 2011-01-05

Family

ID=24468120

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69740060T Expired - Lifetime DE69740060D1 (de) 1996-03-14 1997-03-13 Nasale verabreichung von substanzen zur behandlung der tardiven emesis

Country Status (24)

Country Link
US (1) US5760086A (de)
EP (1) EP0891186B1 (de)
JP (1) JP2000507234A (de)
KR (1) KR100420673B1 (de)
CN (1) CN1217657A (de)
AT (1) ATE489137T1 (de)
AU (1) AU707467B2 (de)
BG (1) BG102780A (de)
CA (1) CA2248968C (de)
CZ (1) CZ289797B6 (de)
DE (1) DE69740060D1 (de)
DK (1) DK0891186T3 (de)
EE (1) EE03665B1 (de)
ES (1) ES2357520T3 (de)
IL (1) IL126199A (de)
NO (1) NO984245L (de)
NZ (1) NZ331991A (de)
PL (1) PL328940A1 (de)
PT (1) PT891186E (de)
RU (1) RU2181588C2 (de)
SK (1) SK282695B6 (de)
UA (1) UA57733C2 (de)
WO (1) WO1997033573A1 (de)
YU (1) YU40398A (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770262B2 (en) 2000-03-30 2004-08-03 Questcor Pharmaceuticals, Inc. Nasal administration of agents for the treatment of gastroparesis
EA019809B9 (ru) * 2008-11-11 2014-08-29 Юнилевер Нв Композиция черного чая
US20130213393A1 (en) 2009-12-22 2013-08-22 Evoke Pharma, Inc. Nasal formulations of metoclopramide
CA2780485C (en) * 2008-12-22 2017-12-12 Evoke Pharma, Inc. Nasal formulations of metoclopramide
US20110165143A1 (en) * 2010-01-06 2011-07-07 The Regents Of The University Of Colorado, A Body Corporate Modulation of caspases and therapeutical applications
CA2846340A1 (en) 2011-08-25 2013-02-28 Matthew J. D'onofrio Treatment of symptoms associated with female gastroparesis
FR2980976B1 (fr) 2011-10-10 2015-10-16 Mohamed Skiba Composition pharmaceutique pour l'administration par voie nasale de la metopimazine
CN104606136A (zh) * 2015-01-06 2015-05-13 中国人民解放军军事医学科学院毒物药物研究所 甲氧氯普胺鼻腔喷雾剂、其制备方法及用途
US11517545B2 (en) 2016-12-15 2022-12-06 Evoke Pharma, Inc. Treatment of moderate and severe gastroparesis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4624965A (en) * 1984-11-15 1986-11-25 Nastech Pharmaceutical Co., Inc. Novel method of administering anti-nausea and anti-emetic pharmaceutical agents and novel dosage forms containing same

Also Published As

Publication number Publication date
NO984245D0 (no) 1998-09-14
EP0891186A1 (de) 1999-01-20
RU2181588C2 (ru) 2002-04-27
EE9800295A (et) 1999-02-15
ES2357520T3 (es) 2011-04-27
CA2248968C (en) 2005-08-02
YU40398A (sh) 2001-07-10
WO1997033573A1 (en) 1997-09-18
EE03665B1 (et) 2002-04-15
SK125998A3 (en) 1999-03-12
EP0891186A4 (de) 2004-03-31
DK0891186T3 (da) 2011-03-14
PL328940A1 (en) 1999-03-01
IL126199A0 (en) 1999-05-09
KR19990087763A (ko) 1999-12-27
PT891186E (pt) 2011-02-25
AU2210297A (en) 1997-10-01
CN1217657A (zh) 1999-05-26
US5760086A (en) 1998-06-02
JP2000507234A (ja) 2000-06-13
NO984245L (no) 1998-11-11
EP0891186B1 (de) 2010-11-24
NZ331991A (en) 2000-04-28
CZ289797B6 (cs) 2002-04-17
IL126199A (en) 2004-06-01
ATE489137T1 (de) 2010-12-15
CZ292298A3 (cs) 1999-03-17
KR100420673B1 (ko) 2004-07-23
AU707467B2 (en) 1999-07-08
CA2248968A1 (en) 1997-09-18
SK282695B6 (sk) 2002-11-06
BG102780A (en) 2000-01-31
UA57733C2 (uk) 2003-07-15

Similar Documents

Publication Publication Date Title
DE69725171D1 (de) Substituierte pyrrolylverbindungen zur behandlung von entzündungen
ATE225176T1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
DE69600307T2 (de) Beatmungsgerät zur Behandlung von Ateminsuffizienzen
EA199700170A1 (ru) Способ получения некоторых азациклогексапетидов
DE69634951D1 (de) Topische verwendung von betulinsäure zur behandlung bösartiger melanome
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
DE69740060D1 (de) Nasale verabreichung von substanzen zur behandlung der tardiven emesis
ATE239500T1 (de) Kombination von angiotensing-convertin-enzyme hemmern mit diuretikum zur behandlung von störungen der mikrozirkulation
DE60142037D1 (de) Nasale verabreichung von metoclopramid zur behandlung der gastroparese
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
DE69230224D1 (de) Potenzierung von nmda-antagonisten
DK0845988T3 (da) Hidtil ukendte kondenserede isoquinoliner som dopaminreceptorligander
DE69607559T2 (de) Verfahren zur Behandlung von Phenolteer
DE69736180D1 (de) Behandlung von manischen erkrankungen
ATE60788T1 (de) Derivat von p-aminophenol mit mucrosekretolytischer fluessiger und antipyretischer wirksamkeit, dessen verfahren zur herstellung und dessen pharmazeutische zusammensetzungen.
KR970074720A (ko) 촉진제, 분무 물질 및 그를 사용한 분무 방법
DE69917445D1 (de) Reinigung von carboxaldehyd
DE3878529D1 (de) Vorrichtung zur behandlung von verstauchungen, insbesondere der sprunggelenke sowie zur vermeidung von dabei auftretenden bestimmten komplikationen.
ATE194915T1 (de) Intranasales antimigränemittel
DE69329994T2 (de) Arylalkoxyphenoxyimidazolinverbindungen
ATE284706T1 (de) Neue verbesserte formulierung zur behandlung von thromboembolismus
DE69413325T2 (de) 24-Epi-1alpha-Hydroxyvitamin D2 zur Behandlung von Osteoporosis
DE69833655D1 (de) Methoden und zusammensetzungen zur behandlung der hyperlipidämie